Technical Analysis for SZLS - Stagezero Life Sciences Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 0.040 | 0.00% | 0.000 |
SZLS closed unchanged on Monday, April 8, 2024, on 3.31 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Nov 12
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bearish Centerline Cross | Bearish | 0.00% | |
| Jack-in-the-Box Bearish | Bearish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | 0.00% | |
| 50 DMA Resistance | Bearish | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| Volume Surge | Other | 0.00% |
| Alert | Time |
|---|---|
| No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. | |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2024-11-12
StageZero Life Sciences Inc., formerly GeneNews Ltd, is a Canada-based company focused on developing and commercializing molecular diagnostic tests for early detection of cancer. It has developed Sentinel Principle platform technology, which determines biomarkers from whole blood. In additional, the Company offers ColonSentry product, it is a blood test to determine an individual’s current risk for having colorectal cancer. It is developing cancer testing kit Aristotle, which is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood. The Company is also focused on testing Aristotle application on other disease conditions including neurology, gastroenterology, cardiology, and autoimmune disorders.
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Mines Medicine Biotechnology Disease Science Cancer RTT Life Sciences Clinical Medicine Cancers Disorders Cell Biology Neurology Biomarker Cardiology Diagnostic Tests
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Mines Medicine Biotechnology Disease Science Cancer RTT Life Sciences Clinical Medicine Cancers Disorders Cell Biology Neurology Biomarker Cardiology Diagnostic Tests
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.15 |
| 52 Week Low | 0.035 |
| Average Volume | 89,058 |
| 200-Day Moving Average | 0.054 |
| 50-Day Moving Average | 0.044 |
| 20-Day Moving Average | 0.045 |
| 10-Day Moving Average | 0.046 |
| Average True Range | 0.004 |
| RSI (14) | 45.36 |
| ADX | 12.34 |
| +DI | 36.276 |
| -DI | 30.710 |
| Chandelier Exit (Long, 3 ATRs) | 0.044 |
| Chandelier Exit (Short, 3 ATRs) | 0.051 |
| Upper Bollinger Bands | 0.052 |
| Lower Bollinger Band | 0.037 |
| Percent B (%b) | 0.21 |
| BandWidth | 34.607 |
| MACD Line | 0.000 |
| MACD Signal Line | 0.001 |
| MACD Histogram | -0.0008 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.040 | ||||
| Resistance 3 (R3) | 0.040 | 0.040 | 0.040 | ||
| Resistance 2 (R2) | 0.040 | 0.040 | 0.040 | 0.040 | |
| Resistance 1 (R1) | 0.040 | 0.040 | 0.040 | 0.040 | 0.040 |
| Pivot Point | 0.040 | 0.040 | 0.040 | 0.040 | 0.040 |
| Support 1 (S1) | 0.040 | 0.040 | 0.040 | 0.040 | 0.040 |
| Support 2 (S2) | 0.040 | 0.040 | 0.040 | 0.040 | |
| Support 3 (S3) | 0.040 | 0.040 | 0.040 | ||
| Support 4 (S4) | 0.040 |
